Company: PTPI
Filing Date: 2025-02-14
Form Type: S-1/A
Source: 0001410578-25-000137
Chunk: 245

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-14
Form: S-1/A
Chunk 245
---
 value:

| ​                                        
 ​                                        
 Description                              
 Liabilities:                             | ​ 
 ​ |     ​ 
     ​ 
 Level | ​ 
 ​ | ​           
 December 31 
 2023        
 ​           |         ​ |
|:-----------------------------------------|:--|------:|:--|:------------|----------:|
| Bifurcated embedded derivative liability |   |     3 | ​ | $           | 3,550,000 |

The following table sets forth a summary of the change in the fair value of the warrant liability that is measured at fair value on a recurring basis:

| ​                                                              
 Balance on December 31, 2022                                   | ​ | ​ |           ​ 
           — |
|:---------------------------------------------------------------|:--|:--|------------:|
| Issuance of warrants reported at fair value                    | ​ |   |  21,544,000 |
| Change in fair value of warrant liability                      | ​ |   | -13,974,000 |
| Reclassification of warrant liability to equity upon amendment | ​ | ​ |  -7,570,000 |
| Balance on December 31, 2023                                   | ​ | $ |           — |

F-31

The following table sets forth a summary of the change in the fair value of the bifurcated embedded derivative liability that is measured at fair value on a recurring basis:

| ​                                                                           
 Balance on December 31, 2022                                                | ​ | ​ |          ​ 
          — |
|:----------------------------------------------------------------------------|:--|:--|-----------:|
| Issuance of convertible preferred stock with bifurcated embedded derivative | ​ |   |  6,140,000 |
| Change in fair value of bifurcated embedded derivative                      | ​ |   | -2,590,000 |
| Balance on December 31, 2023                                                | ​ | $ |  3,550,000 |

21) Related Party Transactions On November 28, 2023, the Board approved a payment to JCP III AIV of $ 125,000in recognition of various management and advisory services previously provided to the Company by JCP III AIV.

F-32

INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) PETROS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS

| ​                                                                                                                                                                                                                                                                                                                                                                                                                                      
 ​                                                                                                                                                                                                                                                                                                                                                                                                                                      
 ​